Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 15, 2017JAMA Oncology

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

GBGideon M. BlumenthalLZLijun ZhangHZHui Zhang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Blumenthal et al. (2017) studied this question.

synapsesocial.com/papers/6a1bb16d1567d2fc4d5ed4a9https://doi.org/10.1001/jamaoncol.2017.1029
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reporting results of cancer treatment1981 · 7,867 citations
  2. 2Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy2015 · 52 citations
  3. 3FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 12016 · 368 citations
  4. 4Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab2016 · 758 citations
  5. 5Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial2011 · 289 citations